US And Australia Medical Device Trial Strategy

Mobius helps MedTech sponsors decide whether a US-only, Australia-only, New Zealand-supported, or multi-region clinical pathway is the right fit for their device, evidence goals, regulatory plan, budget, timelines, and operational risk.

Talk to Mobius about trial strategy

Choose the pathway before the protocol is locked

Country selection is an evidence strategy decision. The wrong choice can create avoidable delay, duplicated work, poor site fit, unclear regulatory value, or a trial that is too difficult for sites to run.

Evidence

Start with the decision the clinical data needs to support.

Feasibility

Test country, site, population, endpoint, and workflow assumptions early.

Risk

Prevent rescue risk before the study model becomes expensive to change.

A practical decision framework

Mobius helps sponsors compare pathway options against the decisions that matter.

Evidence goal. What decision must the study support: FDA-facing, TGA/HREC, investor, clinical, reimbursement, commercial, or internal design iteration?

Population and site fit. Can the target population be found and followed at the proposed sites, in the proposed country, under the proposed protocol?

Endpoint practicality. Are endpoints clinically meaningful, measurable, and workable in the proposed setting?

Timeline, budget, and rescue risk. Are assumptions realistic enough to avoid a study that opens but cannot deliver?

US-only, Australia-only, New Zealand, or multi-region

There is no universal best country strategy for a medical device trial. A US-only study may be appropriate when evidence needs to be generated directly in the US healthcare environment. Australia or New Zealand may be appropriate when the sponsor needs practical early evidence, specialist sites, or a staged pathway. A multi-region study may be appropriate when broader patient access, generalisability, or staged evidence generation matters.

Mobius helps sponsors decide which model is practical, defensible, and aligned with the next milestone.

View medical device CRO support in Australia

View Australia trial support for US MedTech companies

Australia for US MedTech ->

Evidence portability needs to be planned

Evidence generated in one country is not automatically useful in another. For medical device sponsors, portability depends on how well the population, clinical setting, device use, operator training, endpoints, follow-up, safety reporting, and data quality align with the decision the evidence needs to support.

Mobius does not promise regulatory acceptance. We help sponsors build a clinical evidence strategy that is coherent, practical, and easier to defend.

Explore regulatory-aware evidence planning

Regulatory planning ->

Site fit matters more than country labels

A country strategy only works if the right sites can deliver the study. Medical device trials often depend on patient access, trained clinicians, procedure volume, imaging or diagnostic workflows, device accountability processes, data entry discipline, and enough operational capacity to manage study requirements.

The goal is not simply to open sites. The goal is to activate sites that can generate reliable evidence.

Explore clinical trial strategy

Clinical trial strategy ->

Preventing rescue risk before it starts

Many trial rescue problems begin during strategy and planning. The protocol is too complex, endpoints are hard to measure, the wrong sites are selected, training is underestimated, recruitment assumptions are optimistic, monitoring is under-scoped, or vendor responsibilities are unclear.

Mobius helps sponsors identify these risks before study start.

Explore clinical trial rescue CRO support

Study rescue support ->

Questions sponsors ask about US and Australia trial strategy

Short answers for sponsors comparing US-only, Australia-only, New Zealand-supported, or multi-region clinical pathways.

Should a medical device sponsor run a trial in the United States or Australia?

It depends on the evidence goal, regulatory pathway, patient population, endpoint strategy, site access, budget, timeline, and future use of the data. Mobius helps sponsors compare US-only, Australia-only, New Zealand-supported, and multi-region approaches before the study design is locked.

Can Australian or New Zealand clinical data support a US medical device evidence strategy?

It may be useful, but evidence portability is not automatic. Sponsors need to consider study population, clinical setting, endpoints, device use, data quality, and alignment with the future regulatory or commercial decision.

Does Mobius support US-only medical device studies?

Yes. Mobius supports US-only medical device studies as well as studies across Australia, New Zealand, and the United States. The right model depends on the sponsor's evidence needs and operational constraints.

Can Mobius help before we choose trial countries or sites?

Yes. Mobius can help with early trial pathway strategy, feasibility planning, site profile development, endpoint review, recruitment assumption testing, and rescue-risk review before the sponsor commits to a country strategy or CRO model.

Does Mobius provide FDA, TGA, or HREC regulatory advice?

Mobius supports regulatory-aware clinical evidence and operational planning, and works alongside sponsor regulatory teams and advisers where needed. We help connect the clinical strategy and trial operations to the evidence the sponsor needs, but we do not replace specialist regulatory or legal advice.

Talk to Mobius ->

Talk to Mobius before you commit to a trial pathway

Tell us what evidence you need, what milestone the trial must support, where you are considering running the study, and what assumptions are driving the plan.

Schedule A Call